- Home
- ITOS vs CERS Comparison
ITOS vs CERS Comparison
Compare ITOS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- CERS
- Stock Information
- Founded
- ITOS 2011
- CERS 1991
- Country
- ITOS United States
- CERS United States
- Employees
- ITOS N/A
- CERS N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- CERS EDP Services
- Sector
- ITOS Health Care
- CERS Technology
- Exchange
- ITOS Nasdaq
- CERS Nasdaq
- Market Cap
- ITOS 342.6M
- CERS 324.3M
- IPO Year
- ITOS 2020
- CERS 1997
- Fundamental
- Price
- ITOS $8.32
- CERS $1.79
- Analyst Decision
- ITOS Strong Buy
- CERS Buy
- Analyst Count
- ITOS 3
- CERS 3
- Target Price
- ITOS $33.67
- CERS $3.17
- AVG Volume (30 Days)
- ITOS 543.4K
- CERS 1.8M
- Earning Date
- ITOS 11-12-2024
- CERS 10-30-2024
- Dividend Yield
- ITOS N/A
- CERS N/A
- EPS Growth
- ITOS N/A
- CERS N/A
- EPS
- ITOS N/A
- CERS N/A
- Revenue
- ITOS $35,000,000.00
- CERS $176,229,000.00
- Revenue This Year
- ITOS $271.18
- CERS $26.47
- Revenue Next Year
- ITOS N/A
- CERS $11.48
- P/E Ratio
- ITOS N/A
- CERS N/A
- Revenue Growth
- ITOS N/A
- CERS 14.71
- 52 Week Low
- ITOS $7.54
- CERS $1.38
- 52 Week High
- ITOS $18.75
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- ITOS 39.51
- CERS 52.76
- Support Level
- ITOS $7.54
- CERS $1.63
- Resistance Level
- ITOS $8.38
- CERS $2.03
- Average True Range (ATR)
- ITOS 0.53
- CERS 0.12
- MACD
- ITOS 0.01
- CERS -0.00
- Stochastic Oscillator
- ITOS 35.94
- CERS 52.94
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.